Management of anticoagulation before and after gastrointestinal endoscopy

American Journal of Gastroenterology

Volumn 104, Issue 12, 2009, Pages 3085-3097

  Kwok, Avelyn ^a   Faigel, Douglas O ^b  

^a UNIVERSITY OF SYDNEY   (Australia)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BLOOD CLOTTING FACTOR 7; CLOPIDOGREL; DESMOPRESSIN; DIPYRIDAMOLE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; FRESH FROZEN PLASMA; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NONSTEROID ANTIINFLAMMATORY AGENT; PROTAMINE SULFATE; PROTHROMBIN COMPLEX; PROTON PUMP INHIBITOR; THIENOPYRIDINE DERIVATIVE; VITAMIN K GROUP; WARFARIN;

ANTICOAGULANT THERAPY; ANTICOAGULATION; BLEEDING; COMORBIDITY; CORONARY ARTERY DISEASE; CORONARY STENT; DEEP VEIN THROMBOSIS; DRUG SAFETY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; HEART ATRIUM FIBRILLATION; HEART VALVE PROSTHESIS; HIGH RISK PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; LUNG EMBOLISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; THROMBOEMBOLISM;

ANTICOAGULANTS; COMORBIDITY; ENDOSCOPY, GASTROINTESTINAL; GASTROINTESTINAL HEMORRHAGE; HUMANS; PATIENT CARE PLANNING; PLASMA; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE CARE; PRACTICE GUIDELINES AS TOPIC; PREOPERATIVE CARE; PROTHROMBIN; PROTON PUMP INHIBITORS; RISK ASSESSMENT; RISK FACTORS; THROMBOEMBOLISM; VITAMIN K;

EID: 72949091261     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2009.469     Document Type: Review

References (117)

1. Eisen GM, Baron TH, Dominitz JA et al. Guideline on the management of anticoagulation and antiplatelet therapy for endoscopic procedures. Gastrointest Endosc 2002;55:775-779
2. Zuckerman MJ, Hirota WK, Adler DG et al. ASGE guideline: the management of low-molecular-weight heparin and nonaspirin antiplatelet agents for endoscopic procedures. Gastrointest Endosc 2005;61:189-194
3. Veitch AM, Baglin TP, Gershlick AH et al. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut 2008;57:1322-1329
4. Tabibian N. Acute gastrointestinal bleeding in anticoagulated patients: a prospective evaluation. Am J Gastroenterol 1989;84:10-12
5. Thomopoulos KC, Mimidis KP, Theocharis GJ et al. Acute upper gastrointestinal bleeding in patients on long-term oral anticoagulation therapy: endoscopic findings, clinical management and outcome. World J Gastroenterol 2005;11:1365-1368
6. Choudari CP, Rajgopal C, Palmer KR. Acute gastrointestinal haemorrhage in anticoagulated patients: diagnoses and response to endoscopic treatment. Gut 1994;35:464-466
7. Wilcox CM, Truss CD. Gastrointestinal bleeding in patients receiving longterm anticoagulant therapy. Am J Med 1988;84:683-690
8. Rubin TA, Murdoch M, Nelson DB. Acute GI bleeding in the setting of supratherapeutic international normalized ratio in patients taking warfarin: endoscopic diagnosis, clinical management, and outcomes. Gastrointest Endosc 2003;58:369-373
9. Wolf AT, Wasan SK, Saltzman JR. Impact of anticoagulation on rebleeding following endoscopic therapy for nonvariceal upper gastrointestinal hemorrhage. Am J Gastroenterol 2007;102:290-296
10. Kuwada SK, Balm R, Gostout CJ. The risk of withdrawing chronic anticoagulation because of acute GI bleeding. Am J Gastroenterol 1996;91:1116-1119
11. Warkentin TE, Crowther MA. Reversing anticoagulants both old and new. Can J Anesth 2002;49: S11-25.
12. Hirsh J, Fuster V, Ansell J et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. Circulation 2003;107:1692-1711 (Pubitemid 36397341)
13. Van Ryn-McKenna J, Cai L, Ofosu FA et al. Neutralization of enoxaparineinduced bleeding by protamine sulfate. Thromb Haemost 1990;63:271-274
14. Vilahur G, Choi BG, Zafar MU et al. Normalization of platelet activity in clopidogrel-treated subjects. J Thromb Haemost 2007;5:82-90.
15. Juergens CP, Yeung AC, Oesterle SN. Routine platelet transfusion in patients undergoing emergency coronary bypass surgery after receiving abciximab. Am J Cardiol 1997;80:74-75
16. Yang X, Disa J, Rao AK. Effect of 1-desamino-8-D-arginine vasopressin (DDAVP) on human platelets. Thromb Res 1990;59:809-818
17. Mannucci PM. Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders. Blood 1988;72:1449-1455
18. Castaman G, Bona ED, Schiavotto C et al. Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. Haematologica 1997;82:584-587
19. Mannucci PM, Vicente V, Vianello L et al. Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986;67:1148-1153
20. Stanworth SJ, Birchall J, Doree CJ et al. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia. Cochrane Database Systematic Review 2007 April 18; (2): CD005011.
21. Yao MD, von Rosenvinge EC, Groden C et al. Multiple endoscopic biopsies in research subjects: safety results from a National Institutes of Health series. Gastrointest Endosc 2009;69:906-910
22. Cappell MS, Abdullah M. Management of gastrointestinal bleeding induced by gastrointestinal endoscopy. Gastroenterol Clin North Am 2000;29:125-167
23. Mensink PB, Haringsma J, Kucharzik T et al. Complications of double balloon enteroscopy: a multicenter survey. Endoscopy 2007;39:613-615
24. Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992;15:347-351
25. MacRae FA, Tank KG, Williams CB. Toward safer colonoscopy: a report on the complications of 5000 diagnostic or therapeutic colonoscopies. Gut 1983;24:376-383
26. Masci E, Toti G, Mariani A et al. Complications of diagnostic and therapeutic ERCP: a prospective multicentre study. Am J Gastroenterol 2001;96:417-423
27. Muehldorfer SM, Stolte M, Martus P et al. Diagnostic accuracy of forceps biopsy versus polypectomy for gastric polyps: a prospective multicentre study. Gut 2002;50:465-470
28. Eswaran SL, Sanders M, Bernadino KP et al. Success and complications of endoscopic removal of giant duodenal and ampullary polyps: a comparative series. Gastrointest Endosc 2006;64:925-932
29. Wexner SD, Garbus JE, Singh JJ et al. A prospective analysis of 13,580 colonoscopies. Reevaluation of credentialing guidelines. Surg Endosc 2001;15:251-261
30. Nelson DB, McQuaid KR, Bond JH et al. Procedural success and complications of large-scale screening colonoscopy. Gastrointest Endosc 2002;55:307-314
31. Ahmad NA, Kochman ML, Lon WB et al. Efficacy, safety, and clinical outcomes of endoscopic mucosal resection: a study of 101 cases. Gastrointest Endosc 2002;55:390-396
32. Freeman ML, Nelson DB, Sherman S et al. Complications of endoscopic biliary sphincterotomy. N Engl J Med 1996;335:909-918
33. Cotton PB, Lehman G, Vennes JA et al. Endoscopic sphincterotomy complications and their management: an attempt at consensus. Gastrointest Endosc 1991;37:383-393
34. Metman EH, Lagasse JP, d'Alteroche L et al. Risk factors for immediate complications after progressive pneumatic dilation for achalasia. Am J Gastroenterol 1999;94:1179-1185
35. Scolapio JS, Pasha TM, Gostout CJ et al. A randomized prospective study comparing rigid to balloon dilators for benign esophageal strictures and rings. Gastrointest Endosc 1999;50:13-17
36. Dormann A, Meisner S, Verin N et al. Self-expanding metal stents for gastroduodenal malignancies: systematic review of their clinical effectiveness. Endoscopy 2004;36:543-550
37. Telford JJ, Carr-Locke DL, Baron TH et al. Palliation of patients with malignant gastric outlet obstruction with the enteral Wallstent: outcomes from a multicenter study. Gastrointest Endosc 2004;60:916-920
38. Kozarek RA, Ball TJ, Brandabur JJ et al. Expandable versus conventional esophageal prostheses: easier insertion may not preclude subsequent stent-related problems. Gastrointest Endosc 1996;43:204-208
39. Schapiro GD, Edmundowicz SA. Complications of percutaneous endoscopic gastrostomy. Gastrointest Endosc Clin N Am 1996;6:409-422
40. AffiA, Vazquez-Sequeiros E, Norton ID et al. Acute extraluminal hemorrhage associated with EUS-guided fine needle aspiration: frequency and clinical significance. Gastrointest Endosc 2001;53:221-225
41. Varadarajulu S, Eloubeidi MA. Frequency and significance of acute intracystic hemorrhage during EUS-FNA of cystic lesions of the pancreas. Gastrointest Endosc 2004;60:631-635
42. Eloubeidi MA, Tamhane A, Varadarajulu S et al. Frequency of major complications after EUS-guided FNA of solid pancreatic masses: a prospective evaluation. Gastrointest Endosc 2006;63:622-629
43. Mathus-Vliegen EM, Tytgat GN. Analysis of failures and complications of neodymium: YAG laser photocoagulation in gastrointestinal tract tumors. A retrospective survey of 18 years'experience. Endoscopy 1990;22:17-23.
44. Piai G, Cipolletta L, Claar M et al. Prophylactic sclerotherapy of high risk esophageal varices: results of a multicentric prospective controlled trial. Hepatology 1988;8:1495-1507
45. Schmitz RJ, Sharma P, Badr AS et al. Incidence and management of esophageal stricture formation, ulcer bleeding, perforation, and massive hematoma formation from sclerotherapy versus band ligation. Am J Gastroenterol 2001;96:437-441
46. de Franchis R, Primignani M. Endoscopic treatments for portal hypertension. Semin Liver Dis 1999;19:439-455
47. Eisen GM, Baron TA, Dominitz JA et al. Complications of upper GI endoscopy. Gastrointest Endosc 2002;55:784-793
48. DiPrima RE, Barkin JS, Blinder M et al. Age as a risk factor in colonoscopy: fact versus fiction. Am J Gastroenterol 1998;83:123-125
49. Sorbi D, Norton I, Conio M et al. Postpolypectomy lower GI bleeding: descriptive analysis. Gastrointest Endosc 2000;51:690-696
50. Nelson DB, Freeman ML. Major hemorrhage from endoscopic sphincterotomy: risk factor analysis. J Clin Gastroenterol 1994;19:283-287
51. Lloyd-Jones DM, Wang TJ, Leip EP et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042-1046
52. Frost L, Engholm G, Johnsen S et al. Incident stroke after discharge from the hospital with a diagnosis of atrial fibrillation. Am J Med 2000;108:36-40.
53. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154:1449-1457
54. Gage BF, Waterman AD, Shannon W et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001;285:2864-2870
55. Andersen LV, Vestergaard P, Deichgraeber P et al. Warfarin for the prevention of systemic embolism in patients with non-valvular atrial fibrillation: a meta-analysis. Heart 2008;94:1607-1613
56. Blacker DJ, Wijdicks EFM, McClelland RL. Stroke risk in anticoagulated patients with atrial fibrillation undergoing endoscopy. Neurology 2003;61:964-968
57. Cannegieter SC, Rosendaal FR, Briet E. Thromboembolic and bleeding complications in patients with mechanical heart valve prostheses. Circulation 1994;89:635-641
58. Bonow RO, Carabello BA, Chatterjee K et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006;48: e84-231.
59. Salem DN, O'Gara PT, Madias C et al. Valvular and structural heart disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:593S-629S.
60. Oxenham H, Bloomfield P, Wheatley DJ et al. Twenty year comparison of a Bjork-Shiley mechanical heart valve with porcine bioprostheses. Heart 2003;89:715-721
61. Heras M, Chesebro JH, Fuster V et al. High risk of thromboemboli early after bioprosthetic cardiac valve replacement. J Am Coll Cardiol 1995;25:1111-1119
62. Tinker JH, Tarhan S. Discontinuing anticoagulant therapy in surgical patients with cardiac valve prostheses. Observations in 180 operations. JAMA 1978;239:738-739
63. Katholi RE, Nolan SP, McGuire LB. Living with prosthetic heart valves. Subsequent noncardiac operations and the risk of thromboembolism or hemorrhage. Am Heart J 1976;92:162-167
64. Antithrombotic Trialists'Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
65. Berger JS, Roncaglioni MC, Avanzini F et al. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006;295:306-313
66. King SB III, Smith SC Jr, Hirshfeld JW Jr et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: A Report of the American College of Cardiology/American Heart Association task Force on Practice Guidelines:2007 writing group to review new evidence and update the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention, writing on behalf of the 2005 writing committee. Circulation 2008;117:261-295
67. Becker RC, Meade TW, Berger PB et al. The primary and secondary prevention of coronary artery disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:776S-814S.
68. Cutlip DE, Baim DS, Ho KK et al. Stent thrombosis in the modern era: a pooled analysis of multicenter coronary stent clinical trials. Circulation 2001;103:1967-1971
69. Ferrari E, Benhamou M, Cerboni P et al. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol 2005;45:456-459
70. Iakovou I, Schmidt T, Bonizzoni E et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA 2005;293:2126-2130
71. Airoldi F, Colombo A, Morici N et al. Incidence and predictors of drug-eluting stent thrombosis during and after discontinuation of thienopyridine treatment. Circulation 2007;116:745-754
72. Kearon C. Natural history of venous thromboembolism. Circulation 2003;107: I22-30.
73. Baglin T, Luddington R, Brown K et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003;362:523-526
74. Kearon C, Kahn SR, Agnelli G et al. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:454S-545S. (Pubitemid 351892971)
75. Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960;1:1309-1312
76. Lagerstedt CI, Olsson CG, Fagher BO et al. Need for long-term anticoagulant treatment in symptomatic calf-vein thrombosis. Lancet 1985;326:515-518
77. Kearon C, Hirsh J. Management of anticoagulation before and after elective surgery. N Engl J Med 1997;336:1501-1511
78. Hui AJ, Wong RMY, Ching JYL et al. Risk of colonoscopic polypectomy bleeding with anticoagulants and antiplatelet agents: analysis of 1657 cases. Gastrointest Endosc 2004;59:44-48
79. Kim HS, Kim TI, Kim WH et al. Risk factors for immediate postpolypectomy bleeding of the colon: a multicenter study. Am J Gastroenterol 2006;101:1333-1341
80. Sawhney MS, Salfiti N, Nelson DB et al. Risk factors for severe delayed postpolypectomy bleeding. Endoscopy 2008;40:115-119
81. Friedland S, Soetikno R. Colonoscopy with polypectomy in anticoagulated patients. Gastrointest Endosc 2006;64:98-100.
82. Wysokinski WE, McBane RD, Daniels PR et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc 2008;83:628-629
83. Douketis JD, Johnson JA, Turpie AG. Low-molecular-weight heparin as bridging anticoagulation during interruption of warfarin: assessment of a standardized periprocedural anticoagulation regimen. Arch Int Med 2004;164:1319-1326
84. Spyropoulos AC, Turpie AG, Dunn AS et al. Perioperative bridging therapy with unfractionated heparin or low-molecular-weight heparin in patients with mechanical prosthetic heart valves on long-term oral anticoagulants (from the REGIMEN Registry). Am J Cardio 2008;102:883-889
85. Hammerstingl C, Tripp C, Schmidt H et al. Periprocedural bridging therapy with low-molecular-weight heparin in chronically anticoagulated patients with prosthetic mechanical heart valves: experience in 116 patients from the prospective BRAVE registry. J Heart Valve Dis 2007;16:285-292
86. Constans M, Santamaria A, Mateo J et al. Low-molecular-weight heparin as bridging therapy during interruption of oral anticoagulation in patients undergoing colonoscopy or gastroscopy. Int J Clin Prac 2007;61:212-217
87. Spyropoulos AC, Frost FJ, Hurley JS et al. Costs and clinical outcomes associated with low-molecular-weight heparin vs. unfractionated heparin for perioperative bridging in patients receiving long-term oral anticoagulant therapy. Chest 2004;125:1642-1650
88. Amorosi SL, Tsilimingras K, Thompson D et al. Cost analysis of " bridging therapy " with low-molecular-weight heparin versus unfractionated heparin during temporary interruption of chronic anticoagulation. Am J Cardiol 2004;93:509-511
89. Goldstein JL, Larson LR, Yamashita BD et al. Low molecular weight heparin versus unfractionated heparin in the colonoscopy peri-procedure period: a cost modeling study. Am J Gastroenterol 2001;96:2360-2366
90. Douketis JD, Berger PB, Dunn AS et al. The perioperative management of antithrombotic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition). Chest 2008;133:299S-339S.
91. Gerson LB, Triadafilopoulos G, Gage BF. The management of anticoagulants in the periendoscopic period for patients with atrial fibrillation: a decision analysis. Am J Med 2004;116:451-459
92. Basson MD, Panzini L, Palmer RH. Effect of nabumetone and aspirin on colonic mucosal bleeding time. Aliment Pharmacol Ther 2001;15:539-542
93. Nakajima H, Takami H, Yamagata K et al. Aspirin effects on colonic mucosal bleeding: implications for colonic biopsy and polypectomy. Dis Colon Rectum 1997;40:1484-1488
94. YousfiM, Gostout CJ, Baron TH et al. Postpolypectomy lower gastrointestinal bleeding: potential role of aspirin. Am J Gastroenterol 2004;99:1785-1789
95. Shiffman ML, Farrel MT, Yee YS. Risk of bleeding after endoscopic biopsy or polypectomy in patients taking aspirin or other NSAIDs. Gastrointest Endosc 1994;40:458-462
96. Hui CK, Lai KC, Yuen MF et al. Does withholding aspirin for on week reduce the risk of post-sphincterotomy bleeding? Aliment Pharmacol Ther 2002;16:929-936
97. Hussain N, Alsulaiman R, Burtin P et al. The safety of endoscopic sphincterotomy in patients receiving antiplatelet agents: a case control study. Aliment Pharmacol Ther 2007;25:579-584
98. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001-2015 (Pubitemid 350106708)
99. Sharis PJ, Cannon CP, Loscalzo J. The antiplatelet effects of ticlopidine and clopidogrel. Ann Intern Med 1998;19:394-405.
100. Fork FT, Lafolie P, Toth E et al. Gastroduodenal tolerance of 75 mg clopidogrel versus 325 mg aspirin in healthy volunteers. A gastroscopic study. Scand J Gastroenterol 2000;35:464-469
101. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischemic events (CAPRIE). Lancet 1996;348:1329-1339
102. Diener HC, Bogousslavsky J, Brass LM et al. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, doubleblind, placebo-controlled trial. Lancet 2004;364:331-337
103. Ernst A, Eberhardt R, Wahidi M et al. Effect of routine clopidogrel use on bleeding complications after transbronchial biopsy in humans. Chest 2006;129:734-737
104. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). http://www. fda.gov/cder/drug/early-comm/clopidogrel-bisulfate.htm. Accessed 20 April 2009.
105. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ 2009;180:713-718
106. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 2009;301:937-944
107. Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: The Clopidogrel Medco Outcomes Study. Abstract. Circulation 2008;118: S815.
108. Li XQ, Andersson TB, Ahlstrom M et al. Comparison of inhibitory effects of he proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004;32:821-827
109. Siller-Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J 2009;157:148e1-5
110. Sibbing D, Morath T, Stegherr J et al. Impact of proton pump inhibitors on the antiplatelet effects of clopidogrel. Thromb Haemost 2009;101:714-719
111. Halkes PH, van Gijn J, Kappelle LJ et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-1673
112. Diener HC, Cunha L, Forbes C et al. European Stroke Prevention Study. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
113. Shaheen NJ, Stuart E, Schmitz SM et al. Pantoprazole reduces the size of postbanding ulcers after variceal band ligation: a randomized, controlled trial. Hepatology 2005;41:588-594
114. Uedo N, Takeuchi Y, Yamada T et al. Effect of proton pump inhibitor or an H2-receptor antagonist on prevention of bleeding from ulcer after endoscopic submucosal dissection of early gastric cancer: a prospective randomized controlled trial. Am J Gastroenterol 2007;102:1610-1616
115. Ye BD, Cheon JH, Choi KD et al. Omeprazole may be superior to famotidine in the management of iatrogeniculcer after endoscopic mucosal resection: a prospective randomized controlled trial. Aliment Pharmacol Ther 2006;24:837-843
116. Yamaguchi Y, Katsumi N, Tauchi M et al. A prospective randomized trial of either famotidine or omeprazole for the prevention of bleeding after endoscopic mucosal resection-induced ulceration. Aliment Pharmacol Ther 2005;21 (Suppl 2):111-115
117. Watanabe Y, Kato N, Maehata T et al. Safer endoscopic mucosal resection: preoperative proton pump inhibitor administration. J Gastroenterol Hepatol 2006;21:1675-1680